Vir Biotechnology shares slide on $150 million stock offering
Shares of Vir Biotechnology (NASDAQ:VIR) dropped 15% before the opening bell on Friday after the company unveiled a $150 million public offering of common stock priced at $10 per share.
The clinical-stage biopharmaceutical company plans to sell 15 million shares in the underwritten offering. Vir has also given the underwriters a 30-day option to buy as many as 2.25 million additional shares at the public offering price, before underwriting discounts and commissions.
Vir Biotechnology is selling all the shares in the offering, which is expected to generate $150 million in gross proceeds ahead of underwriting discounts, commissions and offering costs. The deal is slated to close on November 16, 2026, contingent on customary closing conditions.
Leerink Partners, Morgan Stanley and Evercore ISI are serving as bookrunners for the offering.
Vir Biotechnology develops therapies for serious infectious diseases and cancer. Its clinical-stage pipeline includes programs targeting chronic hepatitis delta and multiple PRO-XTEN dual-masked T-cell engagers aimed at validated targets in solid tumor indications. The company also has a portfolio of preclinical programs spanning several oncologic malignancies.